SCHEMBL3784286

SCHEMBL3784286

Cc1ccc(-c2nn(-c3ncccn3)c3ncnc(N)c23)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 11/20 0.61
▸ ABL1 P00519 6/20 0.61
▸ FYN P06241 5/20 0.61
▸ EGFR P00533 5/20 0.61
▸ YES1 P07947 4/20 0.61
▸ RIPK2 O43353 4/20 0.61
▸ KDR P35968 4/20 0.61
▸ KDM4E B2RXH2 3/20 0.61
▸ LYN P07948 3/20 0.61
▸ MTOR P42345 3/20 0.61
▸ ALDH1A1 P00352 2/20 0.61
▸ LMNA P02545 2/20 0.61
▸ LCK P06239 2/20 0.61
▸ PDGFRA P16234 2/20 0.61
▸ PRKACA P17612 2/20 0.61
▸ FRK P42685 2/20 0.61
▸ HTT P42858 2/20 0.61
▸ MAPK9 P45984 2/20 0.61
▸ CSNK1A1 P48729 2/20 0.61
▸ CSNK1D P48730 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13019996 0.87 SRC (0.73) SRCABL1FYNEGFRYES1
SCHEMBL13063877 0.84 SRC (0.82) SRCABL1FYNEGFRYES1
SCHEMBL22364024 0.82 SRC (0.82) SRCABL1FYNEGFRYES1
SCHEMBL13826003 0.79 SRC (0.68) SRCABL1FYNEGFRYES1
SCHEMBL25068862 0.77 NUDT14 (0.68) SRCABL1FYNEGFRYES1
SCHEMBL13840179 0.76 PIK3CD (0.71) SRCABL1FYNEGFRYES1
SCHEMBL12437093 0.76 SRC (0.78) SRCABL1EGFRKDRMTOR
SCHEMBL29391411 0.76 SRC (0.78) SRCABL1EGFRKDRMTOR
SCHEMBL407934 0.76 SRC (1.00) SRCABL1FYNEGFRYES1
SCHEMBL29432587 0.76 SRC (1.00) SRCABL1FYNEGFRYES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
WO-2009062118-A2 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885ABL1 1725/4885FYN 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback